Atzeyo Biosensors, Inc.的动态

2024: A Year of Breakthroughs at VoxCell BioInnovation This year, we launched our first commercial products, gained recognition across the life sciences community, and kickstarted our first European partnership for tissue models. Key Highlights: ?? Funding Success: Closed an oversubscribed seed round! ?? Product Launch: Commercialized our proprietary Universal Bioinks? and biopolymers like Gelatin Methacryloyl (GelMA), delivering cutting-edge solutions for academic and industry innovators. Explore our products and order directly on our website: ?? https://hubs.ly/Q0325b6p0 Plus, watch out for our upcoming tissue model product page—coming soon! ?? Strategic Partnership: Got down to work with our first T-cell therapy collaboration with German partners TheryCell GmbH and the NMI Natural and Medical Sciences Institute Institute. Learn more about the project here: ?? https://hubs.ly/Q0325b3w0 ?? Leadership Growth: Welcomed Marie-Helene Raigneau to our Board of Directors, bringing decades of industry expertise. ?? Industry Recognition: - Winner of Collision Conf 2024 PITCH competition - Honored by Life Sciences BC as a "Company to Watch" - Finalist for Company of the Year – Growth Award at the 2024 Technology Impact Awards (TIAs) - Featured in Wiley Analytical Science Magazine: “Human-Like Cancer Tissue Models: Behind Canada’s First High-Resolution Bioprinter” Thank you to our team, partners, and supporters for an incredible year. Together, we’re transforming drug development and advancing life sciences innovation! #Biotech #3DBioprinting #LifeSciences #PreclinicalResearch #Oncology #TissueModels

In the second instalment of @Citeline Commercial’s annual #ScripAsks series, Scancell’s CEO, Phil L'Huillier alongside other industry leaders and experts, shares his thoughts on the #funding, M&A and #partnering trends that are likely to shape the #biopharma space in the year to come. ? With an increasing focus on transformative therapies that address unmet medical needs, Phil notes that a strong scientific foundation, supported by compelling #ClinicalData, and creativity will be key elements in partnership formation and value creation in 2025. ? Read the full article here: https://lnkd.in/eR65KVNw ? #Oncology #ThoughtLeadership #ImmunoOncology #Innovation #Biotech

While it’s great to celebrate successes, I believe there’s also value in sharing the setbacks. Our Eurostars project at Netabolics was recently rejected. This isn’t the first time, and it definitely won’t be the last, but it gives me a chance to share a couple of important thoughts. First, I’m still fully committed to our mission of transforming drug discovery and repurposing using genome-scale biosimulation. Second, I’m actively looking for mission-aligned partners to help move this technology forward. If you’re curious, take a moment to check out the video below. It’s a quick look at what we’re working on, including an example we recently presented at the #RExPO24 conference. It’s a bit technical, but intentionally so. While publication isn't our top priority right now, we also expect to have a full paper ready by mid-late next year. If you’re part of an academic lab or a biotech company and want to collaborate, let’s talk. Together, we can push innovation forward for the benefit of patients. https://lnkd.in/dskcf5AY #PrecisionOncology #Partnerships

We are thrilled to announce our participation in the AFDD Antifibrotic Drug Development Summit in Boston, taking place from today through Thursday! This premier event gathers global leaders in antifibrotic therapies to discuss breakthroughs in drug discovery, translational research, and clinical development for fibrosis-related diseases. ?? At Inoviem Scientific, we’re passionate about accelerating antifibrotic drug development through our technology—a patient-centric approach that delivers unparalleled insights into drug-target interactions and biomarker discovery directly in human tissue. ?? We are particularly excited about the workshop on fibrosis that delves into the latest advancements and challenges in this field. These sessions resonate deeply with our mission to transform the way therapies are developed for fibrotic conditions, bringing meaningful solutions to patients faster. ?? Our team is eager to engage with fellow innovators and explore new partnerships to drive the future of antifibrotic therapies. If you’re attending the summit, let’s connect! Together, we can make a difference in the fight against fibrosis. ?? See you in Boston! #AFDDSummit #Fibrosis #AntifibroticTherapies #DrugDevelopment #Innovation #Biomarkers

Our CEO, Bob Linke, will share a company pitch presentation at 3 pm ET on Wednesday, May 29th, at the 10th Yale Innovation Summit by Yale Ventures. Osmol is honored to participate in this event celebrating ten years of helping develop innovations that impact the world’s greatest challenges. We look forward to creating new connections and opportunities as we continue towards the initiation of clinical development of OSM-205 later this year. OSM-205 is a patented, clinical stage drug with a unique, first-in-class mechanism for modulating intracellular calcium, a known trigger for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), debilitating conditions that can significantly impact both quality of life and survival of cancer patients. Learn more about the summit: https://bit.ly/4bADcj2 #investors #biotech #drugdevelopment

?? Thrilled to be part of this collaboration with NAYA Biosciences! ?? NAYA Biosciences (NASDAQ: NAYA) is developing a groundbreaking new PD-1 x VEGF antibody for cancer treatment, and MAbSilico is proud to be their AI partner in this exciting venture. By combining NAYA's innovative tetravalent scaffold technology with our AI-powered #antibody design expertise, we aim to create a best-in-class therapy with the potential to transform cancer care. This partnership exemplifies MAbSilico's commitment to pushing the boundaries of antibody drug discovery through AI. We're excited to see the impact this collaboration will have on patients' lives. #AIDrugDiscovery #AntibodyEngineering #ImmunoOncology #CancerTreatment #Partnerships #Innovation

We're excited to be investors in the emerging extracellular matrix space. It's early, but the "matrisome" (as Dr. Alexandra Naba from MIT and a company advisor) described the myriad elements which turn cells into tissue, holds promise for novel therapeutics.

Today we are wrapping up another successful edition of the IPF Summit, which brought together over 150 senior decision-makers, academic KOLs, and fibrosis experts to explore and advance pulmonary fibrosis (PF) therapeutics. Key takeaways: ? Emerging Biological Insights: New research is reshaping our understanding of PF. ? Innovative Models: Groundbreaking models are transforming treatment approaches. ? Patient-Centric Focus: Tailoring therapies to diverse patient needs. Thank you to all participants, speakers, and sponsors for your invaluable contributions. Your insights and collaborations are driving PF therapeutics forward. #pulmonaryfibrosis #IPFSummit #innovation #healthcare #research

?? NAYA Biosciences and MAbSilico Team Up to Develop Next-Generation PD-1 x VEGF Antibody for Cancer ?? Exciting news to start the new year! MAbSilico is partnering with NAYA Biosciences (NASDAQ: NAYA) to design a bifunctional #antibody targeting PD-1 x VEGF. The candidate NY-500 is for hepatocellular carcinoma (HCC) and other solid tumors. And guess what? We've partnered with them to leverage our AI-powered antibody design expertise to make NY-500 a best-in-class therapy! ?? Why is this a big deal? - Synergistic Targeting: NY-500 simultaneously targets PD-1 and VEGF, potentially enhancing anti-tumor immune response and disrupting tumor blood vessel formation. - AI-Powered Optimization: Our collaboration with NAYA leverages our cutting-edge AI to refine NY-500's design for improved efficacy and developability. - Building on Clinical Success: Recent data with another PD-1 x VEGF antibody, ivonescimab, showed promising results, surpassing the current standard of care. We're proud to be part of this innovative collaboration, pushing the boundaries of cancer immunotherapy with AI-driven #antibodydesign. Learn more about NAYA Biosciences and their exciting pipeline: https://lnkd.in/eWWpcAar #AIDrugDiscovery #AntibodyEngineering #ImmunoOncology #CancerTreatment #Partnerships #Innovation